ABVX News

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments

Abivax Announces Closing of $920 Million Public Offering

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Launch of Public Offering of American Depositary Shares

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Shareholders to Connect